These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35534911)

  • 41. Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
    George S; Weber DR; Kaplan P; Hummel K; Monk HM; Levine MA
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4163-71. PubMed ID: 26308295
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.
    El-Hajj Fuleihan G; Clines GA; Hu MI; Marcocci C; Murad MH; Piggott T; Van Poznak C; Wu JY; Drake MT
    J Clin Endocrinol Metab; 2023 Feb; 108(3):507-528. PubMed ID: 36545746
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.
    Terpos E; Jamotte A; Christodoulopoulou A; Campioni M; Bhowmik D; Kennedy L; Willenbacher W
    J Med Econ; 2019 Aug; 22(8):766-776. PubMed ID: 30969797
    [No Abstract]   [Full Text] [Related]  

  • 44. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients.
    Fukumoto S; Matsumoto T; Takebe K; Onaya T; Eto S; Nawata H; Ogata E
    J Clin Endocrinol Metab; 1994 Jul; 79(1):165-70. PubMed ID: 8027221
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma - Effective Therapy with Denosumab.
    Harsch IA; Konturek PC
    Am J Case Rep; 2019 Sep; 20():1325-1330. PubMed ID: 31492829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study.
    Zullo AR; Lee Y; Lary C; Daiello LA; Kiel DP; Berry SD
    Osteoporos Int; 2021 Mar; 32(3):565-573. PubMed ID: 33411003
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recurrent hypercalcemia due to ectopic production of parathyroid hormone-related protein and intact parathyroid hormone in a single patient with multiple malignancies.
    Eid W; Wheeler TM; Sharma MD
    Endocr Pract; 2004; 10(2):125-8. PubMed ID: 15256329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
    Nasser SM; Sahal A; Hamad A; Elazzazy S
    J Oncol Pharm Pract; 2019 Dec; 25(8):1846-1852. PubMed ID: 31694497
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
    Diel IJ; Body JJ; Stopeck AT; Vadhan-Raj S; Spencer A; Steger G; von Moos R; Goldwasser F; Feng A; Braun A
    Eur J Cancer; 2015 Jul; 51(11):1467-75. PubMed ID: 25976743
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Humoral hypercalcemia of pregnancy treated with bisphosphonates.
    Koren R; Neeman O; Koren S; Benbassat CA
    Arch Endocrinol Metab; 2018 Feb; 62(1):125-128. PubMed ID: 29694631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuroendocrine Carcinoma as a Cause of Humoral Hypercalcemia of Malignancy: A Case of a Patient With Elevated Parathyroid Hormone-Related Protein.
    Christensen BR; Rendo MJ; Beeler BW; Huddleston BJ; Fenderson JL
    Cureus; 2022 Mar; 14(3):e23398. PubMed ID: 35481321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
    Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
    J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Zoledronate-responsive calcitriol-mediated hypercalcemia in a 5-year-old case with squamous cell carcinoma on the background of xeroderma pigmentosum.
    Colak U; Mutlu GY; Sozmen BO; Yucel EB; Kayserili H; Hatun S
    J Pediatr Endocrinol Metab; 2019 Dec; 32(12):1403-1406. PubMed ID: 31782950
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
    von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
    Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
    Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study.
    Nakamura Y; Kamimura M; Ikegami S; Mukaiyama K; Uchiyama S; Taguchi A; Kato H
    BMC Endocr Disord; 2015 Dec; 15():81. PubMed ID: 26666998
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Denosumab in a pediatric kidney transplant recipient with late, resistant hypercalcemia secondary to Pneumocystis jirovecii pneumonia.
    Beale F; Gkiourtzis N; Koneru S; O'Brien C; Lalayiannis AD
    Pediatr Nephrol; 2024 Aug; 39(8):2355-2358. PubMed ID: 38277030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Denosumab normalized plasma calcium concentration in malignancy-associated hypercalcaemia].
    Størling L; Villadsen GE; Krogh K; Vestergaard P
    Ugeskr Laeger; 2014 Jul; 176(30):. PubMed ID: 25292242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.